Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.

Authors :: Devi K
Shaikh MU
Ali NB
Adil SN
Khan M
Soomar SM
Source :: Leukemia research reports [Leuk Res Rep] 2021 Nov 29; Vol. 16, pp. 100284. Date of Electronic Publication: 2021 Nov 29 (Print Publication: 2021).
Publication Year :: 2021
Abstract: In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to estimate the hazard ratios in patients receiving these treatment regimens considering p-value ≤0.05 significant. The survival rate among double/triple expressor lymphoma patients received R-DA-EPOCH was 82.8%, and 83.3% received R-CHOP. For double/triple expressor lymphoma patients received R-DA-EPOCH. The findings of our study demonstrated that the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar.<br />Competing Interests: The authors declare no competing interest<br /> (© 2021 Published by Elsevier Ltd.)

Full Text Access

Tools